Between November 2020 and March 2023, 574 patients were enrolled in the program. Interim results revealed a remarkable 90.9% treatment success rate among 308 patients, across seven countries.

With support from TB Alliance and the Australian Government, Burnet has partnered with the National Tuberculosis Program in Papua New Guinea to support the roll out of a new all-oral treatment regimen for drug-resistant tuberculosis. The introduction of BPaL/M in Papua New Guinea, follows successful implementation of the treatment in the Philippines, Indonesia, Vietnam and several other countries worldwide.

A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.

The newly inaugurated PeerLINC Knowledge Hub in Manila is poised to harness local expertise and experience to catalyze the adoption of advanced and more efficacious cures for tuberculosis (TB) on a global scale.

March 25, 2024, was the launching of the PeerLinc Knowledge Hub, (Peer-to-peer Learning for Innovative Cures for TB), a project of the TB Alliance which has identified the Tropical Disease Foundation (TDF) to host the project in the Philippines.

TB Alliance’s new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative.

The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Product Development and Access Partnerships program.

A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.

A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.

Interim operational research results from five Central and Southeast Asian countries show that the new, shorter drug-resistant tuberculosis (TB) treatment – BPaL (comprised of bedaquiline, pretomanid, and linezolid) – had a 94.5% cure rate in countries with a high burden of drug-resistant TB (DR-TB).

A ‘dream come true’ drug is on the brink of a national rollout in the Philippines, and could transform life for thousands with resistant TB

— Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± Moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).

While the new BPaL regimen is showing high effectiveness in the treatment of tuberculosis in Ukraine, the war threatens to hamper the success in the long term

Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%.